This multi-author book concerns the applications of monoclonal antibodies in the study, diagnosis and treatment of cancer. It represents the third volume in a series on cancer markers and updates the vast amount of information that is accumulating on the use of monoclonal antibodies in the identification of cancer antigens. The first chapter deals with a brief review on the use of monoclonal antibodies in the study of antigens associated with experimental animal tumours with emphasis on areas of research where these reagents have proven or potential usage. The following chapters concentrate on the human system and focus on individual human tumour types, hormones, major histocompatibility, complex antigens and oncofetal antigens. The chapter on monoclonal carcinoembryonic antigen (CEA) antibodies reviews the use of antibodies in understanding the immunobiology of CEA and also discusses how CEA antibodies can be used in immunohistological diagnosis, tumour imaging and immunotherapy. A chapter on melanoma describes how monoclonal antibodies can be used as probes for the molecular structure and biological function of melanoma-associated antigens. These applications of monoclonal antibodies in the molecular characterisation of tumour If our biologist thought that precancerous epithelial lesions took one or two forms, he should study the book carefully with a sympathetic pathologist on hand to translate the jargon. As it makes no claim to discuss the lesions fully, widespread assumptions will be revealed.
Curiously no definition of cancer is given although this would specify one limit to the subject under study. The authors launch straight into the description. This is classical histopathology: the structure of the biopsy is carefully assessed, and then compared with biopsies (or their descriptions) from earlier cases, whose outcome is known. Experienced histopathologists become skilled at foretelling the future in this way. Here the lesions considered precancerous, collectively called dysplasia, are shown although little is known yet of the associated risk.
The classification by organ and pre-existing disease might worry a biologist but suits the pathologist. Each clinical decision is made against its own background. But the accounts are uneven. The cytological descriptions of dysplasia in ulcerative colitis are very detailed (and well illustrated) but sketchy in adenomas of the same organ (and barely illustrated).
